Scientists used gene therapy and a novel light-sensing protein to restore vision in mice
On Oct. 22, 2020, a newly developed light-sensing protein called the MCO1 opsin restored vision in blind mice…
On Oct. 22, 2020, a newly developed light-sensing protein called the MCO1 opsin restored vision in blind mice…
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
On Oct. 22, 2020, Gilead Sciences announced that the FDA had approved the antiviral drug Veklury (remdesivir) for…
On Oct. 21, 2020, ViiV Healthcare, majority owned by GSK, with Pfizer and Shionogi Limited as shareholders, announced…
On Oct. 20, 2020, the U.S. Department of Defense announced an $87 million, seven-year award to the BioIndustrial…
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…
On Oct. 19, 2020, Thermo Fisher Scientific announced it had received an expansion of its Emergency Use Authorization…
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
On Oct. 19, 2020, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics had received a grant…
On Oct. 16, 2020, BD (Becton, Dickinson) announced the CE mark and European availability of a product for…
On Oct. 16, 2020, the U.S. Department of Defense in coordination with the Department of Health and Human…
On Oct. 15, 2020, the WHO announced Interim that results from the Solidarity Therapeutics Trial, coordinated by the…
On Oct. 14, 2020, the World Health Organization (WHO) announced that prior to the COVID-19 pandemic, many countries…
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of…
On Oct. 13, 2020, Howard Hughes Medical Institute Investigator Leslie Vosshall’s team at The Rockefeller University and colleagues…
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
On Oct. 12, 2020, the Washington University School of Medicine in St. Louis announced a $14.6 million grant…
On Oct. 8, 2020, bioMerieux and the Africa Medical Supplies Platform (AMSP), announced a new partnership to facilitate…
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
On Oct. 7, 2020, the Nobel Prize in Chemistry 2020 was awarded to Emmanuelle Charpentier and Jennifer Doudna…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study…